On June 9, the FDA added bemotrizinol to the list of permitted active ingredients for over-the-counter sunscreens in the United States, the first new UV filter cleared for the market since the late 1990s. [1] The ingredient, also known as BEMT and sold by dsm-firmenich as PARSOL Shield, provides broad-spectrum protection across UVA and UVB rays and has low levels of absorption through the skin, with the FDA deeming it generally recognized as safe and effective for adults and children six months and older. [1] The final order is scheduled to take effect on August 9, 2026, with products expected to reach U.S. retail later in 2026 or in 2027. [3] Because dsm-firmenich sponsored the regulatory application, PARSOL Shield is expected to benefit from an eighteen-month period of U.S. market exclusivity before other manufacturers can use the active more broadly. [2]
The most important beauty story of the week is not that American consumers will soon get one better sunscreen ingredient. It is that one of the American beauty industry’s most technically constrained categories has finally had its rulebook cracked open.
For decades, sunscreen in the United States has lived inside a regulatory paradox. It is one of the most culturally normalized daily skincare products, one of the most medically recommended, and one of the least globally competitive in terms of available filter technology. American consumers were told to wear sunscreen every day, while the domestic market was left to formulate from a narrower and older palette than Europe, Asia, and Australia. The result was a category defined by compromise: elegant enough to use daily, strong enough to defend against UVA, sheer enough for deeper skin tones, comfortable enough under makeup, and stable enough to hold up in real life. U.S. brands could solve some of those problems some of the time, but rarely all of them at once.
That gap created a strange form of underground prestige. The most beauty-literate American SPF customer did not necessarily trade up to the most expensive domestic sunscreen. She imported Japanese, Korean, European, or Australian formulas, often through unofficial channels, because those products felt better and were understood to use newer filters. Sunscreen became one of the few beauty categories where regulatory geography shaped taste itself. The consumer was not merely choosing between brands. She was choosing between national systems.
Bemotrizinol matters because it attacks the weakest point in the American system: the separation between protection and wearability. The active is valued because it is photostable, broad spectrum, and compatible with lighter, clearer textures than many legacy U.S. options. That does not automatically make every future BEMT formula excellent. Formulation remains its own discipline, and a superior active can still be placed inside a mediocre product. But it changes what is possible. For brands that have spent the last decade dressing old filter systems in skincare language, this is a technical reset rather than a marketing refresh.
The first commercial advantage will not belong to the brands with the loudest launch campaign. It will belong to the companies that understood this approval as an inevitability and began development before the final order. Sunscreen is not color cosmetics. It cannot be credibly rushed through the lab, stability testing, claims architecture, packaging compatibility, and retail education in a single season. The earliest winners will likely be the brands and manufacturers that were already preparing for the BEMT era, because they recognized that the bottleneck was regulatory rather than consumer demand.
That is also why the DSM-Firmenich exclusivity period is more consequential than it may first appear. For eighteen months, the early U.S. market for next-generation sunscreen will have a supplier concentration story embedded inside it. PARSOL Shield gives DSM-firmenich both a regulatory trophy and a commercial gatekeeping position at the exact moment beauty brands will want to signal global-level SPF innovation. This is where the story becomes more than dermatology. It becomes ingredient IP, supplier power, product development timing, and retail storytelling all at once.
The contrarian read is that this approval may do more to challenge imported SPF than to threaten legacy American sunscreen. Korean and Japanese sunscreens became cult products in the U.S. partly because they’re seen as better and more modern, but also because they represented access to a superior beauty infrastructure. If American brands can finally close the filter gap, the import advantage becomes less automatic. At the same time, the approval validates the consumer instinct that made those imported products desirable in the first place. American sunscreen was behind. The market knew it long before the regulator moved.
The more exposed players may be the mineral-only and “clean” SPF brands that built their positioning around distrust of chemical filters. For years, they benefited from the weakness of available U.S. chemical options, especially around irritation, opacity, and public anxiety over absorption. A newer filter with low skin absorption and a long record of international use complicates that narrative. It does not eliminate the mineral customer, but it makes the old clean-versus-chemical binary harder to sustain.
Over the next six to twelve months, expect sunscreen to be treated less like seasonal protection and more like a prestige technology race. The claims will move toward UVA performance, photostability, pigment compatibility, post-procedure use, longevity language, and daily compliance. The best brands will resist the urge to treat BEMT as a single-ingredient miracle. The real prize will be a shift toward a new generation of American SPF that finally behaves like modern skincare without asking the consumer to tolerate the category’s stale regulatory past.
Sources
[1] U.S. Food and Drug Administration, “FDA Expands Sunscreen Options for the First Time in 20 Years,” June 9, 2026.
[2] dsm-firmenich, PARSOL Shield / FDA sunscreen active regulatory materials, December 2025 and June 2026.
[3] GQ, “Everything You Need to Know About the New FDA-Approved Sunscreen Ingredient,” June 13, 2026.
